BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has upscaled its private placement offering to 30 million units, aiming to raise $1.5 million for general working capital and to further its business plans following the acquisition of a portfolio from IMV Inc. This strategic financial move is set to bolster the company’s position in developing immunological technologies for oncology and infectious diseases.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
